83602-41-9

Usage

Uses

Different sources of media describe the Uses of 83602-41-9 differently. You can refer to the following data:
1. A non-immunosuppressive analog
2. A non-immunosuppressive analog of Cyclosporin A.

InChI:InChI=1/C64H113N11O13/c1-26-28-29-41(15)53(88-44(18)76)52-57(81)67-45(27-2)59(83)70(20)34-49(77)71(21)47(31-36(5)6)56(80)69-50(39(11)12)61(85)72(22)48(32-37(7)8)55(79)65-42(16)54(78)66-43(17)58(82)75(25)64(19,33-38(9)10)63(87)68-46(30-35(3)4)60(84)73(23)51(40(13)14)62(86)74(52)24/h26,28,35-43,45-48,50-53H,27,29-34H2,1-25H3,(H,65,79)(H,66,78)(H,67,81)(H,68,87)(H,69,80)/b28-26+/t41-,42+,43-,45+,46+,47+,48+,50+,51+,52+,53-,64+/m1/s1

Upstream product

• 121584-52-9 C₆₂H₁₀₉N₁₁O₁₄ 
• 1754-88-7 ethylenetriphenylphosphorane 
• 59865-13-3 cyclosporin A 
• 108-24-7 acetic anhydride 
• 59865-13-3 cyclosporine A 
• 83563-94-4 C₆₄H₁₁₃N₁₁O₁₃ 

Downstream Products

• 59865-13-3 C₆₂H₁₁₁N₁₁O₁₂ 
• 59865-15-5 C₆₂H₁₁₃N₁₁O₁₂ 
• 121584-52-9 C₆₂H₁₀₉N₁₁O₁₄ 
• 121584-08-5 C₆₉H₁₁₅N₁₁O₁₃ 
• 83563-94-4 C₆₄H₁₁₃N₁₁O₁₃ 
• 111722-68-0 C₆₇H₁₁₃N₁₁O₁₂ 
• 111722-68-0 C₆₇H₁₁₃N₁₁O₁₂ 
• 121886-75-7 [(3R,4R)-3-hydroxy-4-methyl-6-(2-hydroxyethyl)-N-MeNle]-1-cyclosporin 
• 286852-20-8 MeLeuValMeLeuAlaDAlaMeLeuMeLeuMeValMeBmt(OAc)AbuSar-Ome 
• 159391-85-2 Acetylcyclosporin 4,7-bis(benzyl thioamidate) 
• 121584-52-9 [(3R,4R)-3-acetyloxy-4-methyl-6-oxo-N-MeNle]-1-cyclosporin 
• 159391-89-6 Cyclosporin 7-(benzyl thioamidate) 

Relevant academic research and scientific papers

Synthesis of [ω-3H-MeBmt1]-cyclosporin A

[3H]-Cyclosporin A labeled at the first amino acid ([ω-3H-MeBmt1]CS) has been prepared by tritium gas hydrogenolysis of [O-acetyl-ω-bromo- MeBmt1]CS followed by deprotection with methanolic sodium methoxide. The requisite bromo intermediate was prepared by bromination of [O-acetyl- MeBmt1]CS with N-bromosuccinimide. After synthesis and purification, 2.45 m8 of [ω-3H-MeBmt1]CS with a total activity of 327 MBq were produced with a radiochemical purity >97%, and specific activity of 160 GBq/mmol (4.3 Ci/mmol).

Semisynthetic Di- and Tri-Functionalized Non-Immunosuppressive Cyclosporin A Derivatives as Potential Anti-HIV 1 Drugs

A regio- and stereoselective synthesis of original semi-synthetic di- and tri-functionalized non-immunosuppressive cyclosporins by way of a Barton ester decarboxylation and a C-thioalkylation starting from cyclosporin A (CsA) and [4′-hydroxy-MeLeu]4-CsA is described.

Development of a practical process for the opening of macrocyclic Cyclosporin a and amino acid deletion

A practical and robust process for the derivatization of Cyclosporin A was demonstrated. The processes rely on the opening of Cyclosporin A and removal of amino acid fragments via Edman degradation, with the isolation of crystalline tetrafluoroboric salts of the corresponding acyclic polypeptides.

Oligopeptide cyclophilin inhibitors: A reassessment

Potent cyclophilin A (CypA) inhibitors such as non-immunosuppressive cyclosporin A (CsA) derivatives have been already used in clinical trials in patients with viral infections. CypA is a peptidyl prolyl cis/trans isomerase (PPIase) that catalyzes slow prolyl bond cis/trans interconversions of the backbone of substrate peptides and proteins. In this study we investigate whether the notoriously low affinity inhibitory interaction of linear proline-containing peptides with the active site of CypA can be increased through a combination of a high cis/trans ratio and a negatively charged C-terminus as has been recently reported for Trp-Gly-Pro. Surprisingly, isothermal titration calorimetry did not reveal formation of an inhibitory CypA/Trp-Gly-Pro complex previously described within a complex stability range similar to CsA, a nanomolar CypA inhibitor. Moreover, despite of cis content of 41% at pH 7.5 Trp-Gly-Pro cannot inhibit CypA-catalyzed standard substrate isomerization up to high micromolar concentrations. However, in the context of the CsA framework a net charge of -7 clustered at the amino acid side chain of position 1 resulted in slightly improved CypA inhibition.

Targeting Extracellular Cyclophilin A via an Albumin-Binding Cyclosporine A Analogue

An albumin-binding CsA analogue 4MCsA was achieved by attachment of a thiol-reactive maleimide group at the side-chain of P4 position of CsA derivative. 4MCsA was semi-synthesized from CsA, and the cell-impermeability of albumin-4MCsA was detected by mass spectrometry and a competitive flow cytometry. 4MCsA exhibits inhibition of chemotaxis activity and inflammation by targeting extracellular CypA without immunosuppressive effect and cellular toxicity. These combined results suggested that 4MCsA can be restricted extracellularly through covalently binding to Cys34 of albumin with its maleimide group, and regulate the functions of cyclophilin A extracellularly.

Synthesis and characterization of bodipy-FL-cyclosporine a as a substrate for multidrug resistance-linked P-glycoprotein (ABCB1)

Fluorescent conjugates of drugs can be used to study cellular functions and pharmacology. These compounds interact with proteins as substrates or inhibitors, helping in the development of unique fluorescence-based methods to study in vivo localization and

NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF

A compound of the Formula (I) is disclosed: (I) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification. Also described are a pharmaceutical composition comprising the same and a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, and liver, and kindey diseases, and hair loss using the same.

CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION

The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

Cyclosporin derivatives for the treatment and prevention of a viral infection

The present invention relates to a compound of the formula (I): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection using the same.

NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF

The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.